Q2 2022 CareCloud Inc Earnings Call
Please standby your conference call will begin momentarily we thank you for your patience and we ask that you. Please remain on the line.
[music].
The care club second quarter 2022 conference call. During the presentation, all participants will be in a listen only mode. Afterwards, we will conduct a question and answer session at that time. If you have a question. Please press the one followed by the four on your telephone keypad.
If at any time during the conference you need to reach an operator. Please press star Zero as a reminder, today's conference is being recorded.
I'd now like to turn the conference over to Kim Flash cared clouds General counsel Ms lunch the floor is yours.
Good morning, everyone welcome to the Coeur cloud second quarter 2022 conference call on.
On todays call are Mahmud Haq, our founder and no no no no no no no no no no no.
Our Chief Executive Officer, President and a director and Bill Korn, Our Chief Financial Officer.
Before we begin I would like to remind you that certain statements made during this conference call are forward looking statements within the meaning of section 27, a of the Securities Act of 1933 as amended and.
And section 21 E of the Securities Exchange Act of 1934 as amended.
All statements other than statements of historical fact made during this conference call are forward looking statements, including without limitation statements regarding our expectations and guidance for future financial and operational performance expected growth business outlook and potential organic growth and acquisition.
Yeah.
Forward looking statements may sometimes be identified with words, such as well.
They expect plan anticipate upcoming believe estimate or similar terminology and the negative of these terms.
Forward looking statements are not promises or guarantees of future performance and are subject to a variety of risks and uncertainties many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward looking statements.
These statements reflect our opinions only as of the date of this presentation and we undertake no obligation to revise these forward looking statements in light of new information or future events.
Please refer to our press release, and our reports filed with the Securities and exchange strategic where you will find a more comprehensive discussion of our performance and factors that could cause actual results to differ materially from these forward looking statements.
One who dialed into the call by telephone you may want to download our second quarter 2022 earnings presentation.
Please visit our Investor Relations site IR.
Dr Kerr cloud Dot com.
Scroll down to news and events.
Click on second quarter, 2022 results conference call and download the earnings presentation.
Finally on today's call, we may refer to certain non-GAAP financial measures.
Please refer to today's press release announcing our second quarter 2022 results for a reconciliation of these non-GAAP performance measures to our.
Our GAAP financial results.
And with that said I'll now turn the call over to our CEO <unk> <unk>.
Thank you Ken and thanks to all of you for joining us for the second quarter earnings call.
On today's call I would like to discuss.
A deeper dive into care cloud record bookings.
Direct result of our newly launched products and heightened focus on organic growth.
We're soon to be launched products for remote monitoring.
A revision to our outlook that is attributable mainly to a delay in our acquisition playbook.
Finally, an update on our sales pipeline.
To start with some highlights of the quarter annualized recurring bookings of the new contracts of $5 5 million.
Excluding onetime fees were the highest in the history of the company almost double what we signed last year and compares to $1 6 million in the first quarter of 2022.
Revenue of $37 2 million was up 9% year over year.
Adjusted EBITDA of $7 million increased 24% over second quarter of last year.
Adjusted net income of $5 6 million increased 23% over the prior year period.
Now taking a closer look at bookings, we are especially pleased with the results this quarter, which are directly correlated with our efforts to drive the organic growth that we have been speaking about the last couple of quarters.
As we have discussed our growth strategy in recent quarters has award from a pure consolidation playbook to one that strikes a balance of accretive acquisitions complimented by organic growth achieved through investment in sales and a lower level as mentioned bookings from recurring sources were $5 5 million.
<unk> up 97% year over year and a record for care club.
Additionally, non recurring professional services bookings of $6 7 million.
Increased more than three times that of second quarter of 2021 view largely due to the acquisition of <unk> that was completed late in second quarter of last year.
Additionally, while we want to stop short of giving bookings guidance you have a high level of confidence that third quarter recurring bookings will meet or exceed those of second quarter and may represent another record for the company.
Importantly, a meaningful component of dumb dumb dumb kings.
Right from contracts for our newly introduced care cloud wellness that launched last quarter.
Specifically greater than 1%.
Nonprofessional services bookings came from other new wellness product demonstrating terrific early reception for this solution.
As a refresher wellness, which launched in late April .
Is an effective way for the old practices to support the treatment and well being of the chronically ill patients that they serve. Additionally, it is a great source of referral revenue with little to no upfront cost.
Witnesses early results demonstrate that its value is clearly resonating with the physician space. While it is not to get too granular around booking metrics. We think it's important to share. This information with you as it ties directly to the conversion of the robust pipeline activity that we provided a lot of details around <unk>.
Last quarter.
Most of all it shows that it would increase investment in product innovation and sales and marketing efforts bearing fruit.
Given the sensitivity around bookings and volatility by quarter. Please note that investors should not expect us to provide bookings metrics every quarter.
We are pleased to be launching our forthcoming remote patient monitoring program this quarter.
Remote patient monitoring our RPM for short is a digital health solution, leveraging the internet of things, which tracks and monitors chronic conditions and potential emergent situation close to real time.
Okay clouds RPM solutions.
Atrix like blood pressure glucose measurements heart rate or both weight and sleep changes and the elderly as well as fetal monitoring.
I'll be instantly transmitted from devices to patients EHR, capturing a longitudinal view of the patient across the care continuum.
We plan to offer a full service to the physician providing care managers supplying the device and helping to populate the EHR with data transmitted from the cloud.
At a minimum our solution promotes connectivity to health care data.
Whenever and wherever it resides and at best can serve.
Situations, and preempt them, improving outcomes and reducing costs in the process.
We are excited to continue along the path of innovation by introducing this revolutionary digital health solution to the market.
Besides the total market opportunity at a north of $100 billion over the next few years.
Drilling down to the medical practice level, we believe a typical practice on average can drive incremental revenue of up to one third annually to a combination of chronic care management and monitoring of which we can capture a meaningful percentage. We note also that the timing of other RPM product launch.
May coincide with CMS is favorable treatment towards the proactive management of chronic conditions.
<unk> increased reimbursement for chronic care management in 2022.
Believe that following additional work by the device providers inclusive of proof points regarding adoption and improvement of outcomes CMS may increase fees for remote monitoring in future years. These favorable rates may serve to incentivize providers to do more monitoring.
With respect to our acquisition strategy and has been the case for some time, we strive to balance accretive acquisitions that integrate well with our cloud platform and deliver value to our shareholders with a reasonable level of organic growth stemming from new customers same store sales and product innovation, while we are.
Happily exceeding expectations with respect to the organic component of our strategy. Our acquisition playbook took a pause through the first half of 2022.
As we outlined in our outlook.
In March our 2022 guidance always contemplated a small amount of acquired growth that would be required to hit our revenue and EBITDA targets.
While the acquisition pipeline remains robust and we continue to evaluate a number of opportunities non felt compelling enough to execute from EBIT accretive or strategic standpoint for one thing private valuation expectations remain lofty. Despite the slide in the public company valuations year to date.
In a recent industry report it was noted that healthcare Tech M&A was down in the first half of 2022 as a quieter struggled with valuation disconnect driven by the big step ups is there anything in lofty post money valuation of the last couple of years.
Given that our criteria for doing a deal requires us to target and ROI over three to four years. This fiscal discipline and selectivity left us with a gap to meeting our full year outlook.
Meanwhile, we are hopeful that private company valuations, maybe in the back half of the year.
In setting our guidance earlier in the year, we incorporated the anticipated taking down of revenue from two customers that came to us as part of our Playa acquisition.
At BTT acquisition the clients I think you are in the process of merging their operations with another health system each.
<unk> had a different EHR mandate from whatever clients for utilizing as such we believe there was a risk that.
And while this potential attrition was factored into our guidance our expectation was to make up the revenue with acquired growth, which is not likely pushed out to 2023.
Accordingly, we now expect revenue in the range of $140 million $243 million.
Versus our prior expectations of $106 million.
$255 million due to an expected shortfall in acquired revenue.
In doing so we are reducing of our EBITDA guidance to a range of $22 million $24 million.
From $24 million to $26 million previously.
I want to recreate that the fundamentals of our business remains strong as evidenced by our record bookings and the absence of any tuck in acquisition is the sole driver of the guidance reduction that bill will expand upon.
Before I turn it over to Bill for his financial review I would like to comment on the health of our sales and pipeline activity.
A fair amount of detail last quarter about how will the increased investment in sales and marketing and product innovation would lead to an uptick in organic growth and we are seeing early success of this in both the funnel of pipeline opportunities as well as bookings Vips that of a pipeline at the end of second quarter.
Was $40 million.
Pushing to increase above the $25 million, we had in the prior year.
Moreover, the incremental pipeline creation was $21 million.
Up 50%.
Higher year period.
Average contract value or deal size increased 42% over second quarter of last year.
As suggestive of two things larger customers in the pipeline and also good with both products and services being delivered a crossover platform.
For example, enterprise accounts were 64% of the pipeline, but small accounts comprised 16% and mid sized practices.
Remaining 20%.
Further as an illustration of increased product density. Our teams are actively working with clients, representing an estimated $50 million in annualized revenue from <unk> cloud wellness, which we introduced in the market just last quarter all toward Dolby fell shy of our required revenue targets through the first half.
The health of our pipeline, our sales motion and bookings strength has never been better in the history of our company.
To summarize.
We delivered record bookings in the second quarter with an expectation for as good if not better in third quarter.
Year to date, we have announced innovative digital health solutions inclusive of wellness for chronic care management and the soon to be launched remote patient monitoring solution.
Our sales and marketing efforts continue to ramp and early results are encouraging as evidenced by care cloud record bookings.
We continue to work through an active acquisition pipeline.
With the goal of completing one or more deals in the back half of this year or early 2023.
Look forward to reporting our progress to you as we navigate through the rest of 2022.
Now I will turn the call over to Ed Woodward, we're closer look at our second quarter results.
Ill.
Thank you Holly and thanks, everyone for joining us on the call today to discuss our second quarter results.
The second quarter was in line with our expectations on.
On today's call I'll review, the quarterly and first half results and discuss our guidance revision in more detail.
For the second quarter, we generated recurring bookings, which will produce annual recurring revenue of $5 $5 million.
Most double what we did in second quarter last year.
How do you noted we do not plan to provide bookings on a quarterly basis going forward as they can be lumpy.
But given our strong second quarter results. We thought you would appreciate the insight today.
It is evident that our organic growth initiatives are starting to take hold as our newer products represent a significant portion of new recurring bookings.
Our second quarter revenue was $37 2 million.
<unk>, an increase of $3 2 million or 9% year over year.
Our GAAP net income of positive $2 $7 million.
Compared very area or $227000 last year.
This represents the fourth quarter in a row, where we've delivered more than $1 million in positive GAAP net income.
Our GAAP net loss per share was <unk> <unk>.
Based on the net loss attributable to common shareholders, which takes into account the preferred stock dividends declared during the quarter.
Alright, non-GAAP adjusted net income was $5 $6 million, an increase of 23% year over year.
Adjusted net income per share was <unk> 37.
Compared to 31 per share for the year ago quarter.
Adjusted EBITDA of $7 million increased 24% year over year and set a new record.
Our adjusted EBITDA margin of 19% increased 220 basis points compared to last year.
And increased 540 basis points sequentially to the highest level since we went public in 2014.
As we continued to reduce cost and drive further efficiencies from our previous acquisitions.
If you look at our results for the first half.
Revenue for the first six months of 2022.
<unk> <unk>.
$6 million, an increase of 14%.
<unk> to $63 8 million in the first six months of 2021 with 85% generated from our technology enabled solutions.
For the first six months of 2022 R gap.
$9 million.
Compared to a GAAP net loss of $2 2 million in the first six months of 2021.
This equates to a loss of 26 per share after subtracting the preferred share dividends.
Our non-GAAP adjusted net income for the first six months of 2022.
$9 1 million or <unk> 60 per share.
During the first half of 2022, our adjusted EBITDA was $11 $7 million, an increase of $2 $4 million or 26% from $9 3 million in the same period last year.
Now I'll turn to the balance sheet and cash flow.
We ended the second quarter with $10 $2 million of cash and equivalents and generated $5 million of cash flow from operations during the quarter and $8 $1 million year to date.
As <unk> mentioned, we are adjusting our guidance to reflect the fact that we have not made any acquisitions yet this year.
Our original guidance for the year assume we will complete one or two tuck in acquisitions during the year.
<unk> approximately $13 million of revenue.
Which would have offset the revenue from the two customer transitions that how do you mentioned.
So we factored in the wind down of this revenue in our guidance, we expect it to replenish the loss of these customers with acquired revenue.
However, we have not yet found a deal on terms, we believe provided a compelling returns to shareholders.
Prefer to pass on a deal close it on terms, which are not as favorable as we would like.
With five months left in the year and the current disequilibrium between public and private valuations.
We think it's unlikely that any potential acquisition will meet the assumptions baked into our original dot dot dot dot dot dot.
We're always looking for game changer deals and we will let investors know when we have something compelling to talk about.
But we have removed any impact from our 2022 guidance.
With that as a backdrop, we now expect 2022 revenue to be in the range of $140 million to $143 million.
Adjusted EBITDA to be in the range of $22 million to $24 million.
Going into the second half of 2022, I'm pleased that our robust product solutions are resonating in the market and our organic growth strategy is starting to take hold.
I look forward to keeping you posted on our progress in the remainder of the year.
With that I'll turn the call over to Mahmud for his closing remarks.
Yeah.
Thank you Bill.
I'd like to thank our employees customers and shareholders for their continued support.
How do you mentioned.
I'm pleased with the expansion of our malls.
Any initiatives Andrew.
Thank you.
We look forward to continuing to update you on our progress.
The.
Thank you.
James.
Okay.
Thank you if you'd like to register a question. Please press the one followed by the four on your telephone.
You will hear a three ton prompt just and I'll, let your request.
Your question has been answered and you would like to withdraw your registration. Please press the one followed by the three.
One moment please for the first question.
And our first question comes from Mr. Cohen with Ladenburg. Please proceed with your question.
Hi, how are you doing the mood can you hear me okay.
Yes, we can good morning.
Wonderful.
Couple of questions. So I guess firstly on the.
The back half guide.
And.
Hi, These comments about the third quarter that was good or not better.
In the second quarter.
Could you talk about the cadence of.
Back half for modeling purposes, it looks like.
Probably 35 or 30.
$35 5 million for Q.
Q3, and Q4 any specific read into the cadence on the back half from your comments.
Sure. Thank you for the question, Jeff and let me get started on the from the booking standpoint, the organic same strategy standpoint that I will turn it over to bill for the back of the year from the financial aspect.
As we mentioned during the script the second quarter. Finally, we were able to hit a record booking numbers on the recurring revenue side. It's five filing with the onetime fee was about $5 7 million. One third of that was coming roughly one third of that was coming from our recently launched.
Project readiness. So based on these additional so one does that in this project and upcoming the motivation monitoring launch, which we will provide the details later in this in the third.
Third quarter and also with the robust pipeline and if I again, just shared the numbers with the pipelines Amit.
At the end of the second quarter, we had about $14 million in Portland pipeline and this is excluding current upsell opportunity from the veteran that standpoint, even just only in the existing client base.
We are actively currently working with up to where the potential possible opportunity of clients generating which could generate about $50 million in annualized revenue of course, we cannot close all of it even if we are able to close let's say half of it over the last one year or two.
So there will be a good number so we'd add with this bank.
I think we are very much in the visibility that we have been at the level of the deals we are.
In the negotiation phase as we are and you have confidence that the third quarter is going to be either same or better than the second quarter in terms of the bookings in the fourth quarter.
Optimistically could even be better than the third quarter, because we anticipate some there's also a little bit more patient monitoring initiative as well.
Okay got it turns or Jeff.
Third quarter, better, but yet.
So that falls outside the Euro guide of.
Up to a $1 43.
So Jeff I guess I would use our.
Guidance for total revenue and there's sort of two factors going into the into the cadence.
As you know normally for US third quarter is our is our biggest quarter. However, we're getting more traction from from new organic customers and as more customers who are signing up.
Who signs up today.
And goes live a month from now well youre going to get it.
A fraction of the quarter during the third quarter and you'll get a full quarter. During Q4. So I think if I were you I would actually spread it and <unk>.
And contrary to normal years actually put a little bit more into fourth quarter, and a little bit less into third quarter.
For 2022.
Okay.
Okay got it and then.
<unk> could you talk a little bit about <unk>.
<unk> crowd force I didn't hear any mention specific.
And how it's Julie.
Thanks, Greg and I will turn the floor to look to in a moment to Karl Johnsen, who is president of the force of Horse-coper initiative, yes.
We've continued to see more and more traction towards the floors.
And if we talk about the.
Our second quarter bookings.
80% was coming.
5% was coming from the <unk> bookings that we had we.
We continue to see more and more in season of our pipeline for the course and we are also seeing some active conversations with some really large opportunities.
From the board standpoint.
Back to <unk>.
The call would you like to.
Excellent.
Okay.
Yes, absolutely. Thank you Heidi.
Certainly what we've seen is.
Continued difficulties.
Hospitals and other large service organization in finding employees.
And I would go on to say that that's not just a U S problem.
Also assume that offshore.
So.
We've been very very pleased with the revenues party mentioned from horse.
The new sales I'm sorry, we're.
25%, which is up from a year ago of about 15%, but a business second quarter in a row that it's been in that range in the pipeline with the deals that hollie mentioned.
Two very substantial deals that are in final stages.
Legal review.
Certainly get us.
In that same range.
Percentage of sales.
So it's really looking very optimistic.
It's really going to morph into a core of what we're doing.
And continue to put forward a new growth. Thank you.
Okay, perfect, but those are for us thanks for taking the questions.
Thanks, Jeff Thank you Jeff.
Our next question comes from Mr. Weisenburger with B Riley Securities. Please proceed with your question.
Thanks. Good morning appreciate you taking the question.
I just wanted to follow up on a comment that was just made about tight labor market conditions domestically and then I think internationally was said.
Does that mean that you are potentially providing some of your services to international customers and is that a change or expansion from any kind of previous scope of work.
Thanks, Good morning Martin.
Yeah sure good car.
Yes, no what I was talking about the services labor services. The workforce expense that we're providing is U S based customers exclusively.
Many of those customers are used to utilizing offshore resources.
With the pandemic and other challenges.
We have also been tight.
Got it understood I appreciate that and then maybe just actually following up on that in the current environment are you seeing changes in terms of your customers.
The customers' ability or willingness to leverage partners with O U S.
Forces and I guess does that any potential change there.
And your customers' preferences open up additional opportunities going forward.
Yes, absolutely I would say youre spot on there.
If we look at the bookings for Q2.
Sure a significant share of those bookings were from organizations, who had had immense challenges using offshore resources in the past.
But because of the pressure that they've had to to get labor.
In the U S. They have not been able to do that.
Turn to offshore resources. So it certainly has opened up some new opportunities for us.
Got it I appreciate that and then as Youre going to market with these expanded offering can you just talk about kind of the value proposition, you're leading with and have you had to change that messaging at all or adapt your pricing strategy and I guess do you anticipate needing to do that going forward to drive.
At adoption.
Okay, Great question Mark.
Core offering that remains the same but if you think about the future of the healthcare and more and more.
The industry is moving towards the digital accounts.
<unk> medicine or more going towards that risk management, the paper performance modules or more proactive health management models.
There has been a significant push from the CMS side as well on the carrier.
The CCM point of view and we believe.
After the call.
Onychia management, the remote patient monitoring is going to get lot more traction and if you think about it more and more devices and on becoming available the wearable devices that significantly has been advanced and from the technology standpoint.
It will become more and more easier for the vendors to collect the data proactively from the patients symptoms point of view and then.
Once that data analyze the data in.
<unk> raised the red flags and alerts into the EHR system. So we have started to step into the same. The next day. We will go next generation initiatives, yes, we even come internally talk about chronic care management, we saw a lot of tremendous.
Excitement tomo for existing client base only and there is I think stone. So we have launched initially from the upsell standpoint, I think over the existing client base because of the tremendous opportunity that was already there and then these new products have become part of the overall offering so from the pricing standpoint from these two services.
I talked about the chronic care management and remote patient monitoring we are providing not only just the services and the technology, but also the resources.
The key managers for example, who will pick up the phone and talk to the patient so the pricing structure for chronic care management and remote patient monitoring is slightly different than our rest of the offering but comprehensive pricing model that takes us for that and offer these to come with the higher revenue models because.
As an example for remote patient monitoring devices will also be inboard and.
And FDA device it will be the embarrassed by the Medicare as an example.
That will also become part of our revenue model.
Very helpful with all of that detail I. Appreciate it and then just two more from me I guess love to hear about the mid <unk> kind of activity and the ability to convert project based revenues to recurring revenue and then just the other one would be I guess as you think about the economy and if it should.
Deteriorate a little further in the back half of the year and maybe into the beginning of next year, how should we think about.
What parts of your business might be impacted the most kind of thinking about exposure maybe to elective procedures or are more discretionary spending from patients. Thank you.
Okay. Thanks.
Thanks, Mark on your first question.
If I just take as an example, if I talk about it before the acquisition of before we acquired Medisoft and year before the acquisition. There are seeing related revenue awards, let's hear about in a million recurring minion Rudolph need revenue and this year. So far we already have closed more than twice.
Of that number.
From the maintenance through the maintenance of our health, whether it's coming directly isn't as an upsell RCM deal or with the help both the.
Cloud floors. So we already have started to see the results in this way. The reason our bookings are up it's a combination of all of those pieces somehow some support from that up sell to the major relationships, our existing core technology and the services that we have been offering and the new projects that we are in the process of launching.
Or have already launched.
The care management, so we do see that Medisoft.
On behalf of <unk> saw more and more sales coming in towards.
The second question the from if you think about it from the <unk> standpoint, only that is a more project based revenue in terms of the consultancy or health system implementation and configuration. So that will continue to be the same we do not see any impact on deck revenue and towards if you just talk about.
The patients from the elective surgeries and those standpoints there were some down force some changes during the call, but even that backlog is coming back now so for the from the at least the early future. If we look at.
<unk> timeframe, we do not see any impact from either one of those things.
Tons.
Yes.
I hope I understood. Thank you very much.
Yes. Thank you okay. Thank you thanks Mark.
Our next question comes from Mr. Clean with Maxim Group. Please proceed.
Yes. Good morning, just following up on remote care and.
Well health.
Just to understand it a little better when you talked about launching remote patient monitoring. This quarter is this new from from your well offering in addition to that and then okay.
You mentioned also.
Some new CMS is going to have some new rates could you go into a little more color on that also.
Good morning, and thank you for the question.
So there's a slight difference between that and the overall context, whether you talk about chronic care management of remote patient monitoring both hard towards one the digital health and the second thing is the preventative health management of the proactive management developing both the patient and chronic here. So the patients that have one or two.
More chronic conditions those are being proactively manage to been to help bolster care providers, the caregivers, who connect with the patient go to the medical records to talk to the patient for a certain number of minutes each month and providing them the guidance, but they shouldn't be doing during the month for example, who are diabetic patients where they can be happy.
Now this fall.
Gave you a little bit under one with the patient looking at the chart of their diabetic results and guide the patient, but the patient could be doing vis vis the exercise of the change in the diet plan or whatever.
There is some change in the medication that needs to be done so that's how that chronic care management.
From the reimbursement standpoint, CMS and the insurances reimbursing the time all provided by the caregivers to the patient and electronic management guidelines. So in the bigger picture SDM to this will reduce the hospitalization rates and they already have started to see the change in the hospital.
<unk>. So this was the fluids step towards that preventative.
Touristic Health management now the next level is going to be the remote patient monitoring devices will be in ward. If you think about the economy. Just only that you are talking to the patient and asking the question by looking at the existing charts and the based on the questions that came together will be asking in the sector.
One for example, if you're a meeting we had in the smart watch, which can capture your blood pressure youre oxygen level.
But then the night so that data is automatically over the internet gets transmitted to the EHR gets complied and meaningful alerts gets fired to the doctor and the Doctor can pick up the foreign aid call the patient and asking Denmark ABC that oxygen level has dropped your temperature is high you may have.
ABC problem come and see us for the treatment.
Go to a lab for the lab test as a basic as a simple example, so in terms of the reimbursement.
The government the CMS increased the rate for our chronic care management in 2022 automotive downward almost doubled on the on the search.
Procedure basis.
For remote patient monitoring and this year they did not do that and we believe that the one of the reason is the highest.
From the adoption standpoint, it was a little more time for the patient to adapt to these two convinced to use these devices for the a better a better made of the healthcare. So based on these we believe is the more lenders are coming and the results and outcomes.
We'll be available the CMS should be increasing hopefully the reimbursement to get at more attractive download over the next few years. So our uniqueness is going to be the same on the remote patient monitoring as well we will provide a comprehensive solution the devices the <unk>.
<unk> form of our technology platform.
Services when it comes to RCM that we will make sure that the claims from those extra from those services get submitted to the right insurance at the right you see and get reimbursed at the right level and the third thing is that can't get roads as well so it's going to be a comprehensive solution and arcade and integrated fully integrated with.
Our EHR and practice management platform.
Alright. Thank you my last that's very helpful. Barry.
Formative my last question has to do with churn.
Nick.
Really key question here is what should we think that normalized churn is because.
As you talk I mean, if you did $5 $5 million.
Bookings, if we think about that if that's like $22 million a year and let's say you have.
Recognize half of that is revenue of $11 million.
<unk> that by like around $140 million of revenue that is like 7% organic growth, but but you haven't but that's before churn. So we recognized that there were two big events that happened, but just going forward what should we think normalized churn should be so that how we should think.
About net organic growth. Thank you.
Thank you Andy Great question.
Let's go back if I talk about the last three years. Excluding these two outliers that to clients, we talked about those were like a calculated risk.
There is a high level of risk and the visibility at the time of acquisition and we baked that into our valuation when we are acquiring the companies. Excluding those two outliers. Our 2020 Gen was about 10% and we highlighted that.
So and then 2021, the improved dig down to about.
Eight 7% for the year in terms of revenue and for 2022 right. Now we are on track to hit somewhere between 80% to 90% debt sale. So thats above what churn. Excluding these outliers and I think in this industry anything around 1% a month as a norm and it seemed like DXP.
<unk> been doing better than 1% per month for the last few years and it is continuously improving and again.
This one outlier outlier site now towards your other question, yes that is right in terms of the organic growth.
So far.
If you look if you think about it we have been entirely focused on growing through the acquisition or most of all if you can just talk about the balance it was mostly a positive growth and very small focus on renewed focus on the organic growth the organic sales over the last few years and primarily the last two years and then the last in this year.
In the second half of the last year. We finally have started to see some Brazil, so organic growth activities, whether it's the marketing or the sale of the increase.
The number of employees on the sales and marketing we hired the leadership, we started focusing on other marketing and brand recognition activities. So those have started to bear fruit and therefore, the second quarter is the highest one record in our history.
And with all of that I mentioned earlier, our third and fourth quarter looks like it's going to be even better than that so the 2023. The way we are looking at it and we will provide the guidance towards the at the beginning of the next year, we believe with everything.
Horizon, although visibility next year should come as organic.
Organic growth is in the same double digit organic growth year for us excluding any acquisition.
Okay.
Really helpful. Thank you so much.
Great. Thank you.
As a reminder to register for a question. Please press the one followed by the four on your telephone.
And our next question comes from Mr. Larson with Pete <unk>. Please proceed.
Hi.
CMS has proposed physician fee schedule, they talk a lot about shifting everybody and to value based care and all of the major health plans are talking about digital first products that have value based care wrapped around them. So with this wellness solution in a remote patient monitoring.
<unk> solution first of all with that $5 5 million in bookings over what time period is that going to get recognized is that like can we think about that on an on an annual basis and then secondly, like can you give a sense for what the infill potential is into your existing customer. So if every one of your existing clients purchased the wellness platform.
Just any sense or color around what that total dollar revenue potential could in theory be.
Great. Thanks, David for the question good morning.
Yes, you are right from the CMS.
Digital for Us and that is the reason I think that we're focused at the same time. In addition to our core offering whether it's a practice management or the EHR revenue cycle, we already have started to invest.
And that technology from the <unk>.
Revenue ramp up standpoint, if I, excluding bad necessarily most patient monitoring typically for small practices. It's about 30 to 60 days for 1% to five practices that we start recognizing the revenue pharma midsized practices for up to 25 provider that could be somewhere between three to six months and the August .
Six months to close to any year on an enterprise client 25, plus provider clients and this is also based on the type of service. They have they're looking forward to get from us. So I think the average timeframe. It comes down to about six months for US there and we are able to start recognizing the revenue out of these bookings for Vale.
We do not have much data with US right now because it's just hardly at three months into this but you already have need lie.
Clients, who would generate about close to 600000, plus an annualized recurring revenue out of one third of the bookings that we had in the last year.
In the last quarter. So my whole point is that literally within the first three months, we were able to make about.
Hello, roughly five planes fly within those three months timeframe. So that's still.
That should help in giving some color on the <unk>.
Ongoing life perspective.
For the same case on the remote data monitoring standpoint.
In the fourth quarter after the launch that Tom withstanding could be it could be slightly.
More than the awareness because in this case the <unk>.
Hardware devices would be anymore, those needs to be sent to the patient patient needs to be trained to do it they need to be convinced to use it. So the growing lifetime can be slightly thats, what we are predicting but we need to see as we get into the get into the next year.
<unk>.
Okay.
And then and then any sense for the <unk> potential if all of your customers purchase the wellness Hum.
Perfect and so if you think I mentioned in the second quarter for wellness, we already have and out of the bookings of $5. Five we closed one third of that was coming from the wellness. There is roughly the same number and actually slightly higher which is already out for signature.
And our so far.
Gains out of when the contract is out for signature that virtually 100%. So we anticipate that to be close in addition to that outlook for existing client base fostered a viewing everything over crunching the data and the numbers there is a roughly $15 million in annualized recurring revenue we can get.
Every single client existing client signs up.
Onshore business, so thats roughly the number of Reorders and a 50 $50 million is not going to get signed but that the full potential for opportunity in the existing client base now in terms of the remote patient monitoring.
Just because of the adoption rates all this $50 million virtually would also be eligible for the remote patient monitoring and even more than that beyond that because it's not necessary that you would only go forward remote patient monitoring in the case, which is at this moment reimbursable by by the insurance or the Medicare you can to begin.
Doctors can still monitor the patient and can call them for a different appointment based on debt monitoring. So we think we believe that even that potentially is going to be more than that $50 million debt being at this moment.
We are going after four residents program.
Great. Thanks, very much and then one more quick one in the wellness solution can you talk a little bit about your costs. So if you have like an Uber like model, where a member can basically access of home health individual or a nurse or docs thrown Uber like solution.
Are you paying those providers on like a per hour basis. So that the revenue is matched with a cost or are those sort of full time salaries that.
You are covering.
Yes. Good question. Thank you so one devices and other.
Patients will get our branded devices to alert provider to their practices will then sign up for remote patient monitoring and the FDA. Some of the features some of the devices arent. The only FDA approved those will even get reimbursed by the Medicare So the patient won't even have to pay for those devices. The second part is.
Of course of our technology and the third the third thing, which I talked about was that.
The care managers. So one of the factors can opt to have their own providers, where they can provide can reach out to the patient and provider of those services or they can just keep working as it is without the change in <unk> provides them a full turnkey solution devices platform revenue cycle.
And also the caregiver the care managers. So can management can take the first step by connecting to the patient. If there is a problem and then can handle dawood at a certain point through that provider all guiding to provider. This is taylor.
We have received onto our chronic care management call. This is a concern and then the provider can take the next step. So yes. In this scenario, we will be paying those can manage it and that will be part of the overall pricing package for the client.
Great. Thanks, very much appreciate it.
Great. Thank you.
Okay.
Our next question comes from Mr. D D with H C. Wainwright. Please proceed.
Alright. Thanks.
Just real quick back on the care manager part of the wellness solution.
I understand that you'll be bringing the first touch but.
Just wondering if those people are medical professionals.
Or just relationship managers.
And.
Where are you in building your staff.
To support that activity.
Good morning, Kevin Good question. Thank you for the question.
It's this combination Kevin.
There has it could be nurse practitioner under the supervision of a doctor or just the relationship managers under the supervision of the nurse practitioners. So there is a clear guidelines from the CMS and those managers gave you again managers have to be compliant with those requirements and thats exactly.
What it is in some cases, they may be using some external help in if needed.
We already have that staff available.
Up and running and that's why I mentioned that you already five clients have gone live and there will be already has started to take to get started you start to take care of omnicare conditions observations.
Okay.
Thanks Heidi.
$40 million pipeline I know you've talked to this a little bit but could you.
I guess it just hasnt gelled for me could you just sort of review how long you think.
It will take to convert it all understand a certain percentage short term, but I'm. Just wondering if you expect to earn and burn at all or if it.
And it's absolutely solid sign business.
Or is it just feedback from sales on prospective business.
Great Tim.
This $40 million that we're talking about has already gone through that.
The prospects increase the initial connection has been made so we know that at some stage of <unk> been with agents.
Any company, who is doing the deal not all of them can be converted and for us of course over the initial conversion rates with non res, which every quarter.
Seamlessly improving <unk>.
Organic growth engine is getting further matures.